Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title" }, "data": [ { "type": "Grant", "id": "5334", "attributes": { "award_id": "NNX08AX76G", "title": "\"THE XMM-LSS SURVEY: RE-OBSERVATION OF A05 POINTINGS AFFECTED BY RADIATION\" We propose to re-observe 19 XMM-LSS AOS fields significantly affected by radiation during A05 operations. They are part of the XMM Large Programme dedicated to full coverage of th", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2008-07-23", "end_date": "2010-09-29", "award_amount": 0, "principal_investigator": { "id": 18724, "first_name": "CAROL", "last_name": "LONSDALE", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "\"THE XMM-LSS SURVEY: RE-OBSERVATION OF A05 POINTINGS AFFECTED BY RADIATION\" We propose to re-observe 19 XMM-LSS AOS fields significantly affected by radiation during A05 operations. They are part of the XMM Large Programme dedicated to full coverage of th", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4785", "attributes": { "award_id": "1216660", "title": "\"Weyl Law at 100\"", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "ANALYSIS PROGRAM" ], "program_reference_codes": [], "program_officials": [], "start_date": "2012-09-01", "end_date": "2013-08-31", "award_amount": 12002, "principal_investigator": { "id": 16602, "first_name": "Maciej", "last_name": "Zworski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 176, "ror": "", "name": "University of California-Berkeley", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 176, "ror": "", "name": "University of California-Berkeley", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract (Zworski, 1216660)\n\nThis award provides funding to help defray the expenses of participants, especially women, graduate students, postdocs, and junior faculty, in the \"The Weyl Law at 100\" conference that will be held from September 19--22, 2012, at the Fields Institute for Research in Mathematical Sciences in Toronto, Canada. In 1912 Hermann Weyl published his paper establishing the Weyl law which gives the leading asymptotic description for the counting function of eigenvalues of the Dirichlet or Neumann Laplacian on a bounded domain in the Euclidean space. He later conjectured the form of the second term in asymptotics of the counting functions. After contributions by \nmany mathematicians, among them, Courant, Hilbert, Agranovitch, Levitan, Hormander, Seeley, Duistermaat, Guillemin, Melrose and Sjostrand, the Weyl conjecture was solved by Ivrii in 1982. The workshop is intended as a forward-looking celebration of the 100th anniversary of Weyl's paper. Among the directions to be explored are the (conjectured) connection between random matrix theory and \nhigh energy distribution of differences between eigenvalues, probabilistic Weyl laws for non-self-adjoint \noperators, distribution of scattering resonances and fractal Weyl laws, and physical experiments related to quantum chaos and inverse problems. \n\nAll of the conference topics are central to analysis and are extremely active areas of research. The conference will bring together a broad spectrum of accomplished researchers thereby providing ample opportunities to develop collaborative interactions, and the format \nof the meeting is such that young people will have ample opportunities to speak and be otherwise engaged in the various conference activities.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8941", "attributes": { "award_id": "1U18FD007495-01", "title": "'COVID-19' Incorporation of SARS-CoV-2 primers into a targeted NGS panel for surveillance use in cats", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-08-31", "award_amount": 77500, "principal_investigator": { "id": 24771, "first_name": "Rebecca Penrose", "last_name": "Wilkes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, the viral cause of COVID-19, has infected at least 94 pet cats in the United States, based on confirmed cases by the USDA. Many infections in cats are asymptomatic, and there are only a few ongoing surveillance studies in companion animals, so the number of cases in cats is likely higher. Cats are infected by SARS-CoV-2 from their human owners but have been shown experimentally to transmit the virus cat-to-cat. Once infected, at least experimentally, the virus quickly adapts in cats through genetic drift and positive selection at important residues within the spike protein, a protein used for cellular attachment. These adapted viruses are then spread to additional cats and maintained within the group. This can lead to accelerated fixation of potentially concerning variants for the human population if the virus is then able to re-infect humans. Additionally, cats may serve as a means for introducing variant viruses into wildlife populations based on their hunting behavior. Therefore, surveillance of cats for SARS-CoV-2 is warranted based on these considerations. Targeted surveillance should involve the interface of humans and animals, as this is most likely where these events will occur (infection of animals from humans with a potential of spillback to humans from animals). Pet cats in positive SARS-CoV-2 households are already known to be at risk for infection and should be included in a targeted active surveillance program involving domestic cats. Additionally, some cats show respiratory signs when infected with SARS-CoV-2, so the inclusion of SARS-CoV-2 testing, along with testing for the more likely pathogens that produce respiratory disease in cats, allows for additional passive surveillance. Cats submitted to diagnostic labs for necropsies can also easily be included in a surveillance program. To address surveillance needs, the Purdue Animal Disease Diagnostic Laboratory proposes to add SARS-CoV-2 primer sets to the targeted next-generation sequencing panel for detection of infectious diseases of dogs and cats. The amended panel will be validated for the detection of SARS-CoV-2 by using a set of sequenced positive samples, which contains all the current SARS-CoV-2 variants of interest and concern, as defined by the CDC. Additionally, nasal and oropharyngeal swabs will be collected from cats for surveillance testing based on the above criteria. These samples will be tested by both an approved RT-PCR for SARS-CoV-2 and the targeted NGS panel to determine the diagnostic sensitivity/specificity of the panel for detection of SARS-CoV-2. Additionally, any positive samples we obtain from the cats will be sequenced to evaluate variants associated with infection. Addition of this virus to commonly used panels for infectious diseases will allow for continued passive surveillance without the need to specifically request and obtain approval for the testing. This should enhance our detection of this virus in cats, potentially preventing the unwanted introduction or spread into new populations.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6911", "attributes": { "award_id": "2U01TW010107-06", "title": "1/2 - Regional GEOhealth Hub Centered In Peru-Peru", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 13005, "first_name": "Christine", "last_name": "Jessup", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-09-28", "end_date": "2027-02-28", "award_amount": 299995, "principal_investigator": { "id": 9093, "first_name": "William", "last_name": "Checkley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22747, "first_name": "GUSTAVO F", "last_name": "GONZALES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22748, "first_name": "Stella Maria", "last_name": "Hartinger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22749, "first_name": "Nelson K", "last_name": "Steenland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1531, "ror": "", "name": "UNIVERSIDAD PERUANA CAYETANO HEREDIA", "address": "", "city": "", "state": "", "zip": "", "country": "PERU", "approved": true }, "abstract": "In Latin America, about 172 million or 58% of the population, live in 366 cities comprising over 100,000 residents, all of which have ambient air pollution (AAP) levels above WHO recommended level of 10 μg/m3 annual average for PM2.5. Exposure to AAP, both short and long-term, is associated with higher morbidity and mortality from cardiovascular and respiratory diseases, and there is increasing evidence for Alzheimer’s disease and dementia as well. AAP in Lima, Peru’s largest city, averaged 25 μg/m3 in 2010-2016. The 2nd largest city, Arequipa, averaged 72 μg/m3 at a downtown monitor in 2018. Both cities are far above WHO guidelines of 10 μg/m3. As in many other LMICs, AAP monitoring in Peru is limited; most observations taken by the government are limited to Lima and to a few ground monitors. We propose to extend our prior (2010-2016) 1 k2 -resolution PM2,5 model for Lima through 2025, and also develop a new Lima model for NO2. With these data we will study the association of traffic and air pollution in Lima and evaluate possible different mitigation strategies in terms of reducing air pollution and related respiratory diseases. We will also study the association of AAP and COVID-19 (and all pneumonia) incidence, mortality, and case-fatality in Lima in the year before vaccination was introduced; Peru was hit hard by COVID-19, and has the highest COVID-19 mortality rate in the world. We will also assess whether severe COVID-19 is associated with cognitive deficits 2-4 years afterwards, comparing 100 cases with 100 controls. In addition, we will conduct the first study of Alzheimer disease (AD) and fronto-temporal dementia (FTD) and air pollution in Lima, taking an advantage of an ongoing cohort study with over 500 cases and 500 controls, conducted by a leading Alzheimer’s disease center; in this study we will also assess whether Alzheimer’s disease cases, or fronto-temporal dementia cases were more likely to have had COVID than controls. We also plan to develop a national model for PM2.5 for Peru as a whole, with 5 k2 resolution, and a corresponding data base of hospital data and emergency room visits for all the major cities of the country. With these data we will estimate premature mortality from cardiovascular and respiratory disease due to PM2.5 in Peru. We may also be able to extend our study of Alzheimer’s disease to other urban centers outside of Lima. We will furthermore study possible mitigation strategies for PM2.5 nationwide, which will reduce both PM2.5 and greenhouse gases (produced from many of the same sources), and study their impact on Peru’s obligations to reduce greenhouse gases under the Paris accord.", "keywords": [ "Address", "Adult", "Affect", "Age", "Air Pollution", "Alzheimer&apos", "s Disease", "Applications Grants", "Area", "Asthma", "Automobile Driving", "COVID-19", "COVID-19 mortality", "Cardiovascular Diseases", "Cardiovascular system", "Case Fatality Rates", "Cessation of life", "Charge", "Chronic Obstructive Pulmonary Disease", "Cities", "Clinic", "Cognition", "Cognitive deficits", "Cohort Studies", "Congestive", "Country", "Data", "Databases", "Death Rate", "Disease", "Emergency department visit", "Environmental Risk Factor", "Exposure to", "Frontotemporal Dementia", "General Population", "Government", "Guidelines", "Health", "Hospitalization", "Hospitals", "Incidence", "Interdisciplinary Study", "Interruption", "Intervention", "Latin America", "Life Cycle Stages", "Life Expectancy", "Link", "Long-Term Effects", "Modeling", "Monitor", "Morbidity - disease rate", "Neighborhoods", "Nerve Degeneration", "Neurology", "Nitrogen Dioxide", "Outcome", "Paris France", "Peru", "Peruvian", "Pneumonia", "Policies", "Policy Maker", "Population", "Premature Mortality", "Publishing", "Questionnaires", "Recording of previous events", "Regulation", "Research", "Research Training", "Resolution", "Respiratory Disease", "Series", "Source", "Telephone Interviews", "Time", "Universities", "Update", "Vaccination", "Work", "ambient air pollution", "atmospheric modeling", "base", "burden of illness", "case control", "cognitive function", "cognitive interview", "coronavirus disease", "cost effective", "design", "effectiveness evaluation", "fine particles", "greenhouse gases", "high risk", "improved", "low and middle-income countries", "mortality", "novel", "remote sensing", "residence", "respiratory", "response", "severe COVID-19", "sex", "supplemental oxygen", "traffic-related air pollution" ], "approved": true } }, { "type": "Grant", "id": "8739", "attributes": { "award_id": "1U01DA055343-01", "title": "1/2 Assessing the Cumulative Impact of Early Life Substance and Environment Exposure on Child Neurodevelopment and Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12931, "first_name": "Janani", "last_name": "Prabhakar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2022-05-31", "award_amount": 11790, "principal_investigator": { "id": 21629, "first_name": "Viren Andrew", "last_name": "D'Sa", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21630, "first_name": "Sean CL", "last_name": "Deoni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ DESCRIPTION What are the neurodevelopmental sequelae of in utero opiate and other substance exposure? The succinct nature of this question masks the complex and multifaceted nature of human neurodevelopment, and the diversity of environmental influences that can mediate or moderate the initial direct effects substances may have on the developing brain. From conception to age 10, our brain undergoes remarkable structural and functional growth. Neurodevelopmental processes that include myelination and synaptogenesis are at their peak, responding to integrative cascades of genetic and environmental interactions as they mature neural systems and provide the foundation for emerging cognitive and behavioral skills. The patterns of this early development reflects adaptation to the child's direct and contextual environments and, thus, the potential impact of in utero substance exposures must be considered within the broader family, psychosocial, economic, and physical environment. Over the past year, these environments have witnessed unprecedented upheaval as a result of the COVID-19 pandemic, impacting children, families, and pregnant individuals with disproportionate impact on lower-income, and racial and ethnic minority families - the very families already shaken by the ongoing opioid crisis. Our proposal aims to understand the neurodevelopmental impact of these converging experiences. We will collect deep multi-level and repeat neuroimaging and behavioral phenotype data, alongside rich contextual measures of environmental exposures centered on the child's lived experience, including social equity and socioeconomic factors. Building from a central hypothesis that brain development is an integrative process that is shaped by prenatal insults (opiate and other substance exposures) and ongoing postnatal influences against a backdrop of social,economic, and health inequalities we will: 1. Characterize the variability of `neurotypical' development, recognizing that multiple pathways reflecting individual adaption may lead to the same outcomes; 2. Examine how in utero substance exposures alter these patterns and pathways; and 3. Take a holistic and integrated approach to understanding how the diversity of a child's environment shapes and modifies brain patterns and outcomes. Achievement of these aims requires a careful and purposefully planned study with unbiased measures, community partners, and representative socioeconomic and demographic populations - communities with well-founded distrust of research and public health workers. At the heart of our proposal is the principle of access. We will reduce traditional barriers to participation using innovative data collection methods and mobile labs to bring the research to under-represented and marginalized communities; and build trusted connections with our participating families through our established community advisory boards and peer navigator networks. Our approach, therefore, aims to clarify the impact of substance exposure on child development whilst shifting the field of developmental neuroscience and substance use to a more equitable standard of research, with generalizable findings that can guide non-punitive public health policies.", "keywords": [ "Achievement", "Address", "Affect", "Age", "Analgesics", "Area", "Attention", "Attitude", "Behavioral", "Birth", "Brain", "COVID-19", "COVID-19 pandemic", "California", "Child", "Child Development", "Childhood", "Cognitive", "Communication", "Communities", "Complex", "Conceptions", "County", "Data", "Data Collection", "Development", "Economics", "Electrocardiogram", "Electroencephalography", "Environment", "Environmental Exposure", "Environmental Risk Factor", "Epidemiologic Methods", "Family", "Fentanyl", "Foundations", "Frequencies", "Genetic", "Genotype", "Growth", "Health", "Health Care Research", "Health Policy", "Health Services", "Heart", "Heroin", "Home", "Human Characteristics", "Individual", "Infant", "Lead", "Learning", "Life", "Light", "Low income", "Magnetic Resonance Imaging", "Masks", "Measurement", "Measures", "Mediating", "Memory", "Methods", "Mother-Child Relations", "National Institute of Drug Abuse", "Nature", "Neighborhoods", "Neonatal Abstinence Syndrome", "Neurocognitive", "Neurosciences", "New England", "Newborn Infant", "Nutritional", "Opioid", "Outcome", "Parent-Child Relations", "Participant", "Pathway interactions", "Pattern", "Physical environment", "Physiology", "Play", "Population", "Process", "Protocols documentation", "Public Health", "Recording of previous events", "Research", "Resources", "Rhode Island", "Sampling", "Sampling Studies", "Science", "Selection Bias", "Services", "Shapes", "Site", "Sleep", "Socioeconomic Factors", "Structure", "Substance Withdrawal Syndrome", "System", "Time", "Tissues", "Trust", "base", "behavioral phenotyping", "brain shape", "caregiving", "cognitive neuroscience", "community engagement", "data harmonization", "demographics", "distrust", "early childhood", "economic disparity", "ethnic minority population", "experience", "fetal", "fetal substance exposure", "health equity", "health inequalities", "high dimensionality", "in utero", "infancy", "innovation", "multimodality", "myelination", "neurobehavior", "neurodevelopment", "neuroimaging", "nutrition", "opioid epidemic", "peer", "phenotypic data", "postnatal", "pregnant", "prenatal", "prenatal exposure", "psychosocial", "racial disparity", "racial equality", "racial minority", "racism", "relating to nervous system", "repository", "skills", "social", "social capital", "social equality", "socioeconomics", "study population", "substance use", "synaptogenesis", "treatment services", "visual tracking" ], "approved": true } }, { "type": "Grant", "id": "15082", "attributes": { "award_id": "4UG3HL164285-02", "title": "1/2 REPRIEVE Extension for Trial Completion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 10288, "first_name": "Patrice", "last_name": "Desvigne-Nickens", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-05-01", "end_date": "2026-04-30", "award_amount": 4747407, "principal_investigator": { "id": 10289, "first_name": "Pamela Susan", "last_name": "Douglas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 10290, "first_name": "STEVEN K.", "last_name": "GRINSPOON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary-Abstract Globally, cardiovascular disease (CVD) burden is increasing and a major cause of mortality among people with HIV (PWH). However, data are not yet available from large trials on an effective primary CVD prevention strategy for PWH. The ongoing REPRIEVE trial will address this critical knowledge gap, hypothesizing that statin therapy, with pleiotropic effects on LDL, immune activation and inflammatory pathways, will modify traditional and nontraditional risks and prevent major adverse cardiovascular events (MACE) in PWH. REPRIEVE is well-positioned to provide high quality, clinically actionable and generalizable information to shift the current paradigm of HIV care, in alignment with the goals of NHLBI and OAR to reduce CVD and improve the overall health of PWH. REPRIEVE has met major challenges, anticipated for a large trial. 7,770 participants (31% female, 43% Black, 25% Latino) were enrolled from over 100 sites in 12 countries, a diverse, generalizable population. Retention is high, >90%. Endpoint (MACE) are accumulating steadily despite a low median ASCVD risk score of 4.5%, consistent with the hypothesis that nontraditional risks contribute to CVD in HIV. The Mechanistic Substudy has met its goal, enrolling over 800 participants for serial coronary CT angiography (CTA) and immune function. Preliminary baseline data from the substudy support our hypothesis, linking plaque to CVD risk but also independently to IL-6 and Lp-PLA2, key indices of immune function and arterial inflammation that are being targeted in REPRIEVE. Moreover, REPRIEVE is being leveraged to assess statin effects on COVID severity, and long-term effects in PWH, critical unanswered questions for the field. REPRIEVE has executed well over 6 years and is fundamentally strong. However, with a long duration of recruitment and protocol revisions to identify the optimal at-risk group given new guidelines, median duration of follow up is still short at 3.5 years. REPRIEVE needs additional time, projected at 2 years, plus a close out year, to collect necessary MACE to ensure adequate power, analyze, and disseminate this data. The pressing need for data from a large global primary prevention trial has only grown since REPRIEVE was initiated. Completion of the trial will protect the value of the initial NIH investment and honor the commitment to our participants and scientific community to meet the Aims of the trial. This application for the Clinical Coordinating Center (CCC) of the REPRIEVE Extension for Trial Completion focuses on the clinical rationale and coordination of the trial. The Data Coordinating Center (DCC) application focuses on data management, including the coronary CTA data of the Mechanistic Substudy, and the statistical rationale for the trial design.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Angiography", "Antibodies", "Antibody Response", "Arterial Fatty Streak", "Biological Factors", "Black race", "CCL2 gene", "COVID-19", "COVID-19 incidence", "COVID-19 severity", "Cardiac", "Cardiovascular Diseases", "Cardiovascular system", "Caring", "Characteristics", "Clinical", "Coagulation Process", "Communities", "Coronary", "Coronary Arteriosclerosis", "Country", "Data", "Data Coordinating Center", "Diet", "Dyslipidemias", "Enrollment", "Ensure", "Environment", "Epidemiology", "Event", "Female", "Fibrin fragment D", "Funding", "Genes", "Genetic", "Glucose", "Goals", "Guidelines", "HIV", "Health", "Heart failure", "Immune", "Immunoglobulin A", "Immunoglobulin G", "Immunologics", "Infection", "Inflammation", "Inflammatory", "Insulin", "Integration Host Factors", "Interleukin-6", "Investments", "Knowledge", "Latino", "Life Style", "Link", "Lipids", "Liver Dysfunction", "Long-Term Effects", "Low-Density Lipoproteins", "Malignant Neoplasms", "Mediating", "Morphology", "Myositis", "National Heart Lung and Blood Institute", "Outcome", "Participant", "Pathway interactions", "Persons", "Phenotype", "Population", "Populations at Risk", "Positioning Attribute", "Prevention strategy", "Prevention trial", "Primary Prevention", "Proteins", "Proteomics", "Protocols documentation", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Safety", "Serotyping", "Severities", "Site", "Smoking", "Symptoms", "T-Lymphocyte", "Time", "United States National Institutes of Health", "Update", "Viral Load result", "adjudication", "attenuation", "burden of illness", "cardiovascular disorder prevention", "cardiovascular disorder risk", "cardiovascular risk factor", "clinical application", "clinically actionable", "cohort", "coronary computed tomography angiography", "coronary plaque", "data management", "efficacy evaluation", "experience", "follow-up", "high risk", "immune activation", "immune function", "improved", "indexing", "lipoprotein-associated phospholipase A(2)", "monocyte", "mortality", "novel", "oxidized low density lipoprotein", "participant enrollment", "pleiotropism", "predictive marker", "prevent", "primary endpoint", "recruit", "transcriptomics", "trial design" ], "approved": true } }, { "type": "Grant", "id": "11377", "attributes": { "award_id": "1UG3HL164285-01", "title": "1/2 REPRIEVE Extension for Trial Completion", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 10288, "first_name": "Patrice", "last_name": "Desvigne-Nickens", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-05-01", "end_date": "2024-04-30", "award_amount": 6567877, "principal_investigator": { "id": 10289, "first_name": "Pamela Susan", "last_name": "Douglas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 10290, "first_name": "STEVEN K.", "last_name": "GRINSPOON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary-Abstract Globally, cardiovascular disease (CVD) burden is increasing and a major cause of mortality among people with HIV (PWH). However, data are not yet available from large trials on an effective primary CVD prevention strategy for PWH. The ongoing REPRIEVE trial will address this critical knowledge gap, hypothesizing that statin therapy, with pleiotropic effects on LDL, immune activation and inflammatory pathways, will modify traditional and nontraditional risks and prevent major adverse cardiovascular events (MACE) in PWH. REPRIEVE is well-positioned to provide high quality, clinically actionable and generalizable information to shift the current paradigm of HIV care, in alignment with the goals of NHLBI and OAR to reduce CVD and improve the overall health of PWH. REPRIEVE has met major challenges, anticipated for a large trial. 7,770 participants (31% female, 43% Black, 25% Latino) were enrolled from over 100 sites in 12 countries, a diverse, generalizable population. Retention is high, >90%. Endpoint (MACE) are accumulating steadily despite a low median ASCVD risk score of 4.5%, consistent with the hypothesis that nontraditional risks contribute to CVD in HIV. The Mechanistic Substudy has met its goal, enrolling over 800 participants for serial coronary CT angiography (CTA) and immune function. Preliminary baseline data from the substudy support our hypothesis, linking plaque to CVD risk but also independently to IL-6 and Lp-PLA2, key indices of immune function and arterial inflammation that are being targeted in REPRIEVE. Moreover, REPRIEVE is being leveraged to assess statin effects on COVID severity, and long-term effects in PWH, critical unanswered questions for the field. REPRIEVE has executed well over 6 years and is fundamentally strong. However, with a long duration of recruitment and protocol revisions to identify the optimal at-risk group given new guidelines, median duration of follow up is still short at 3.5 years. REPRIEVE needs additional time, projected at 2 years, plus a close out year, to collect necessary MACE to ensure adequate power, analyze, and disseminate this data. The pressing need for data from a large global primary prevention trial has only grown since REPRIEVE was initiated. Completion of the trial will protect the value of the initial NIH investment and honor the commitment to our participants and scientific community to meet the Aims of the trial. This application for the Clinical Coordinating Center (CCC) of the REPRIEVE Extension for Trial Completion focuses on the clinical rationale and coordination of the trial. The Data Coordinating Center (DCC) application focuses on data management, including the coronary CTA data of the Mechanistic Substudy, and the statistical rationale for the trial design.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Address", "Angiography", "Antibodies", "Antibody Response", "Arterial Fatty Streak", "Biological Factors", "Black race", "CCL2 gene", "COVID-19 severity", "Cardiac", "Cardiovascular Diseases", "Cardiovascular system", "Caring", "Characteristics", "Clinical", "Coagulation Process", "Communities", "Coronary", "Coronary Arteriosclerosis", "Country", "Data", "Data Coordinating Center", "Diet", "Dyslipidemias", "Enrollment", "Ensure", "Environment", "Epidemiology", "Event", "Female", "Fibrin fragment D", "Funding", "Genes", "Genetic", "Glucose", "Goals", "Guidelines", "HIV", "Health", "Heart failure", "Immune", "Immunoglobulin A", "Immunoglobulin G", "Immunologics", "Incidence", "Infection", "Inflammation", "Inflammatory", "Insulin", "Integration Host Factors", "Interleukin-6", "Investments", "Knowledge", "Latino", "Life Style", "Link", "Lipids", "Liver Dysfunction", "Long-Term Effects", "Low-Density Lipoproteins", "Malignant Neoplasms", "Mediating", "Morphology", "Myositis", "National Heart Lung and Blood Institute", "Outcome", "Participant", "Pathway interactions", "Persons", "Phenotype", "Population", "Populations at Risk", "Positioning Attribute", "Prevention strategy", "Prevention trial", "Primary Prevention", "Proteins", "Proteomics", "Protocols documentation", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Safety", "Serotyping", "Severities", "Site", "Smoking", "Symptoms", "T-Lymphocyte", "Time", "United States National Institutes of Health", "Update", "Viral Load result", "adjudication", "attenuation", "burden of illness", "cardiovascular disorder prevention", "cardiovascular disorder risk", "cardiovascular risk factor", "clinical application", "clinically actionable", "cohort", "coronary computed tomography angiography", "coronary plaque", "coronavirus disease", "data management", "experience", "follow-up", "high risk", "immune activation", "immune function", "improved", "indexing", "lipoprotein-associated phospholipase A(2)", "monocyte", "mortality", "novel", "oxidized low density lipoprotein", "participant enrollment", "pleiotropism", "predictive marker", "prevent", "primary endpoint", "recruit", "risk prediction", "transcriptomics", "trial design" ], "approved": true } }, { "type": "Grant", "id": "14721", "attributes": { "award_id": "1UG3HL168487-01A1", "title": "1/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-02-15", "end_date": "2029-01-31", "award_amount": 820823, "principal_investigator": { "id": 21553, "first_name": "Christopher Ethan", "last_name": "Cox", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Cardiorespiratory conditions such as the acute respiratory distress syndrome (ARDS), congestive heart failure, COVID pneumonia, and sepsis are among the most common causes of mortality and morbidity, They are also notable for high rates of persistent psychological distress symptoms including depression, anxiety, and PTSD that worsen quality of life and outcomes of the underlying conditions, Yet there are few effective strategies able to overcome barriers of limited access to mental health care. Even less is known about distress management among people from structurally disadvantaged backgrounds such as racially and ethnically minoritized populations because of their suboptimal representation in relevant clinical trials. To fill this gap, we developed Blueprint, an adaptive coping skills training intervention, and have optimized it over years of research. We conducted a multicenter RCT (PCORI PFA 195) of a telephone- and web-based version among those recently hospitalized with serious cardiorespiratory conditions, finding that it reduced depression symptoms and improved quality of life among those with elevated baseline distress. Informed by lessons learned about intervention delivery and eligibility criteria, we next conducted a singlecenter pilot RCT (R34 HL 145387) that targeted a broader population and tested a completely automated, self-guided, symptom-responsive mobile app version of Blueprint. We found excellent adherence and a strong effect on depression, anxiety, PTSD, and quality of life compared to control. Given these promising findings, a formal test of the Blueprint adaptive coping skills training intervention's efficacy is needed. Therefore, we propose a 5-year multicenter RCT with 6-month follow up in which 400 cardiorespiratory failure survivors with elevated symptoms of psychological distress post-discharge are randomized to either Blueprint or an Education Program control-both delivered through similar mobile app platforms. Our specific aims will: (1) Test Blueprint vs. control on symptoms of depression, anxiety, PTSD, and quality of life; (2) Determine patient-level characteristics associated with a great treatment response among sociodemographic subgroups of interest, also applying a heterogeneity of treatment effects analysis to identify other groups of clinical relevance; and (3) Ensure off-the-shelf intervention readiness for implementation by using an exploratory mixed-methods hybrid type 1 implementation framework analysis that integrates semi-structured interviews with trial participants and quantitative trial data from Aims 1 and 2. Innovative elements include a fully automated mobile health delivery system that personalizes content in response to changes in symptom trajectories, a focus on racially and ethnically minoritized persons, the integration of a Spanish language intervention version, and strong community engagement. This project addresses national research priorities and could advance the field with a personalizable yet populationfocused therapy that could be scaled broadly and efficiently to enhance mental health equity.", "keywords": [ "Acute Respiratory Distress Syndrome", "Address", "Adherence", "Age", "Anxiety", "Behavioral", "Black race", "COVID-19", "COVID-19 pneumonia", "Characteristics", "Clinical", "Clinical Trials", "Cognitive Therapy", "Colorado", "Congestive Heart Failure", "Coping Skills", "Critical Illness", "Data", "Disease", "Distress", "Education", "Educational Intervention", "Elements", "Eligibility Determination", "Enrollment", "Ensure", "Ethnic Origin", "Failure", "Gender", "Health", "Heterogeneity", "Hispanic", "Home", "Hospitalization", "Hospitals", "Hybrids", "Implementation readiness", "Intervention", "Interview", "Language", "Lead", "Learning", "Mental Depression", "Mental Health", "Mental Health Services", "Methods", "Modeling", "Morbidity - disease rate", "Online Systems", "Oregon", "Outcome", "Participant", "Patients", "Persons", "Population", "Population Heterogeneity", "Post-Traumatic Stress Disorders", "Problem Solving", "Quality of life", "Race", "Randomized", "Reach Effectiveness Adoption Implementation and Maintenance", "Relaxation", "Research", "Research Priority", "Sampling", "Self Direction", "Self Efficacy", "Sepsis", "Severity of illness", "Site", "Socioeconomic Status", "Structure", "Subgroup", "Survivors", "Symptoms", "Telephone", "Testing", "Time", "Training Programs", "Treatment Efficacy", "Work", "clinically relevant", "community engagement", "comparison control", "depressive symptoms", "design", "disadvantaged background", "efficacy testing", "emotion regulation", "ethnic minority population", "experience", "follow-up", "future implementation", "health care delivery", "health equity", "implementation framework", "implementation outcomes", "improved", "innovation", "interest", "intervention delivery", "mHealth", "mobile application", "mortality", "patient population", "physical symptom", "preference", "primary outcome", "programs", "psychological distress", "psychological symptom", "racial minority population", "response", "skills", "social", "social factors", "sociodemographics", "success", "symptom management", "symptom treatment", "therapy design", "treatment effect", "treatment response" ], "approved": true } }, { "type": "Grant", "id": "12107", "attributes": { "award_id": "1UG3HL166785-01A1", "title": "1/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2024-08-31", "award_amount": 1445727, "principal_investigator": { "id": 27970, "first_name": "Jeremy R.", "last_name": "Beitler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27971, "first_name": "Daniel Stuart", "last_name": "Talmor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 771, "ror": "https://ror.org/04drvxt59", "name": "Beth Israel Deaconess Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Acute respiratory distress syndrome (ARDS) is a severe form of lung injury requiring hospitalization in intensive care and often invasive mechanical ventilation in effort to sustain life. ARDS can result from a variety of insults (e.g. pneumonia, sepsis, trauma, and pancreatitis), posing broad risk to the public health. With the COVID-19 pandemic, ARDS has become a leading cause of death in the US and globally. Yet, even pre-pandemic, ARDS occurred in 10% of US ICU admissions and had an associated mortality of 30-45%. Regardless of ARDS etiology, many survivors experience cognitive, psychological, and physical impairments persisting years after the acute illness resolves. Thus, there remains an urgent need to identify effective ARDS therapies. Invasive mechanical ventilation is potentially life-saving, but can worsen lung injury and patient outcomes if not precisely titrated to attenuate lung stress, which varies by patient with overdistension and atelectrauma (repetitive opening/closure of potentially recruitable lung). Alveolar edema and atelectasis reduce the functional aerated lung volume, such that tidal volume scaled to estimated healthy lung size (i.e. 6 mL/kg predicted body weight) may not always prevent overdistension. Similarly, positive end-expiratory pressure (PEEP) is routinely increased to recruit lung in patients with more severe hypoxemia, an approach that may exacerbate overdistension injury in patients most susceptible. An integrated strategy that mitigates the competing risks of atelectrauma and overdistension is needed. The range of lung stress observed in patients with ARDS receiving standard-of-care ventilation is often larger than that observed in healthy adults due to perturbed lung and chest wall mechanics, increasing risk of both atelectrauma and overdistension. In preclinical models and human cohort studies, lung injury and mortality are less when the ventilator is set to maintain lung stress in the healthy normal range. PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI) is a phase III multicenter randomized trial for adults with moderate-severe ARDS that tests whether precise ventilator titration to maintain lung stress within 0-12 cm H2O, the healthy normal range during relaxed breathing, will improve patient outcomes compared to guided usual care. In the precision ventilation arm, PEEP will be individualized to achieve lung stress of 0 cm H2O at end-expiration, and tidal volume individualized to achieve driving pressure of 12 cm H2O or the lowest possible. In the guided usual care arm, PEEP will be adjusted per usual care within limits set to avoid practice extremes; tidal volume of 6-8 mL/kg predicted body weight will be targeted unless plateau pressure exceeds 30 cm H2O, in which case tidal volume will be lowered. We will evaluate the effect of ventilator strategy on 60-day mortality (Aim 1), lung injury (Aim 2), and hemodynamic instability (Aim 3). Findings will help determine the role for individualizing ventilator support to reduce lung stress in ARDS and have potential to improve survival from this leading cause of death worldwide.", "keywords": [ "Acute", "Acute Respiratory Distress Syndrome", "Adipose tissue", "Admission activity", "Adult", "Alveolar", "Anatomy", "Atelectasis", "Attenuated", "Automobile Driving", "Blinded", "Body Weight", "Breathing", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "Cause of Death", "Chest wall structure", "Clinical", "Clinical Management", "Cognitive", "Cohort Studies", "Edema", "Esophagus", "Etiology", "Fibrosis", "Grant", "Healthcare Systems", "Heterogeneity", "Histologic", "Hospitalization", "Human", "Hypoxemia", "Impairment", "Injury", "Insufflation", "Intensive Care", "Intra-abdominal", "Life", "Lung", "Manometry", "Measures", "Mechanical Stress", "Mechanical ventilation", "Mechanics", "Modeling", "Morbidity - disease rate", "Multi-Institutional Clinical Trial", "National Heart Lung and Blood Institute", "Normal Range", "Outcome", "Pancreatitis", "Patient-Focused Outcomes", "Patients", "Periodicity", "Phase", "Pleural", "Pleural effusion disorder", "Pneumonia", "Positioning Attribute", "Positive-Pressure Respiration", "Pre-Clinical Model", "Predisposition", "Public Health", "Pulmonary Edema", "Randomized Controlled Trials", "Recovery", "Relaxation", "Research", "Risk", "Role", "Safety", "Sepsis", "Shapes", "Shock", "Stress", "Structure of parenchyma of lung", "Survivors", "Testing", "Tidal Volume", "Time", "Titrations", "Trauma", "Ventilator", "Ventilator-induced lung injury", "abdominal pressure", "arm", "atelectrauma", "circulating biomarkers", "cost", "experience", "expiration", "hemodynamics", "improved", "lung injury", "lung volume", "mortality", "novel", "personalized approach", "personalized strategies", "pre-clinical", "pre-pandemic", "pressure", "prevent", "psychologic", "randomized trial", "receptor for advanced glycation endproducts", "recruit", "soft tissue", "standard care", "standard of care", "stress reduction", "surfactant", "systemic inflammatory response", "treatment as usual", "usual care arm", "ventilation", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "5921", "attributes": { "award_id": "3U24AA020801-10S2", "title": "1/3 Alcohol Research Consortium in HIV - Administrative Core (ARCH-AC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20228, "first_name": "Deidra", "last_name": "Roach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2011-09-15", "end_date": "2022-08-31", "award_amount": 111144, "principal_investigator": { "id": 20229, "first_name": "GEETANJALI", "last_name": "CHANDER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20230, "first_name": "MARY E", "last_name": "MCCAUL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This competitive renewal application for the Alcohol Research Consortium on HIV (ARCH) builds on and extends our very successful administrative and research accomplishments during our initial NIAAA funding period. ARCH is integrated into a well-established, scientifically productive, national HIV clinical cohort, the CFAR Network of Integrated Clinical systems (CNICS), a network of 8 clinical cohorts and over 30,000 persons living with HIV (PLWH) across the United States. This dynamic cohort provides an ideal scientific platform for long-term study of HIV and alcohol through the collection of comprehensive clinical data and specimens as well as uniformly-collected patient reported outcomes. The ARCH consortium consists of the Administrative Core (ARCH-AC), the epidemiological research component (ARCH-ERA), and an intervention research component (ARCH- IRA). In addition, we have embedded a nascent resource core into each of the research components to capitalize on our expertise and expand our capacity in two new and critical areas of high relevance to HIV and alcohol services and research: the Biostatistics Core (housed in the epidemiology grant ARCH-ERA) and an eHealth Technology Core (housed in the intervention grant ARCH-IRA). The overarching goal of our consortium is to improve clinical outcomes and reduce health disparities among PLWH with alcohol misuse through development and testing of tailored interventions (ARCH-IRA) that are informed by real-time data collection and analysis (ARCH-ERA). Specific themes addressed by our consortium include health disparities, precision medicine, implementation science, state-of-the-art biostatistical methodology, and eHealth technology. The ARCH Administrative Core (AC), the focus of this application, is the U24 that provides the infrastructure for oversight, coordination and direction to the consortium, and facilitates the scientific goals of the epidemiology and intervention components of ARCH. The structure includes: an executive committee; a research steering committee which includes a scientific advisory board; key scientific working groups to conceptualize and implement study aims. ARCH-AC is co-led by national experts in alcohol use disorders and HIV, who have over 30 years of combined scientific experience in conducting epidemiologic and clinical research in HIV/AIDS. The AC provides the critical infrastructure to: 1)Facilitate communication, collaboration and integration among ARCH components and investigators, NIAAA collaborators, Scientific Advisory Board, CHAART and other alcohol/HIV consortia; 2)Oversee implementation of the ARCH scientific epidemiologic and interventional aims; 3)Optimize coordination of ARCH resources among the research projects and with outside groups, particularly the data repositories, epidemiologic/ biostatistics support and the investigational expertise; 4)Promote scientific participation of junior investigators new to the field of alcohol and or HIV; 5)Support dissemination of information by ARCH investigators through presentations, publications, web site maintenance and other strategies for public communication.", "keywords": [ "AIDS/HIV problem", "Address", "Alabama", "Alcohol consumption", "Alcohols", "Area", "Biometry", "Biostatistics Core", "Characteristics", "Clinical", "Clinical Data", "Clinical Research", "Cognition", "Collaborations", "Collection", "Committee Members", "Communication", "Communities", "Continuity of Patient Care", "Data Analyses", "Data Collection", "Development", "Drug usage", "Epidemiology", "Faculty", "Foundations", "Funding", "Goals", "Grant", "HIV", "Health", "Health Services Research", "Hepatitis C", "Information Dissemination", "Infrastructure", "Interdisciplinary Study", "Intervention", "Intervention Studies", "Investigation", "Knowledge", "Leadership", "Link", "Longitudinal Studies", "Maintenance", "Mental Health", "Methodology", "National Institute on Alcohol Abuse and Alcoholism", "Outcome", "Patient Outcomes Assessments", "Patients", "Persons", "Primary Health Care", "Publications", "Research", "Research Personnel", "Research Project Grants", "Resources", "Services", "Specimen", "Structure", "System", "Technology", "Testing", "Time", "Treatment outcome", "United States", "United States National Institutes of Health", "Universities", "Visit", "Washington", "Work", "acronyms", "adjudicate", "age related", "alcohol epidemiology", "alcohol measurement", "alcohol misuse", "alcohol research", "alcohol services", "alcohol use disorder", "brief intervention", "burden of illness", "clinical care", "cohort", "comorbidity", "computerized", "data repository", "eHealth", "epidemiology study", "experience", "health disparity", "implementation science", "improved", "medical schools", "precision medicine", "social", "spelling", "technological innovation", "treatment disparity", "web site", "working group" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1392, "count": 13920 } } }